Pembrolizumab Effective for Patients with Advanced Head and Neck Squamous Cell Carcinoma
PHILADELPHIA (May 23, 2016) —Pembrolizumab, an anti-programmed death cell protein 1 antibody, is successful in treating advanced head and neck squamous cell carcinoma, according to researchers from Fox Chase Cancer Center-Temple Health. This provides a new treatment option with fewer side effects. Presented at ASCO 2016 Annual Meeting.